A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Purpose
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Conditions
- Atopic Dermatitis
- Alopecia Areata
- Hidradenitis Suppurativa
- Vitiligo
- Psoriasis
- Chronic Spontaneous Urticaria
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. - 2. Participant has plans for future visits at the site for continued management of IMISC.
Exclusion Criteria
- 1. Inability to provide written informed consent/assent. - 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Other
Recruiting Locations
Fort Smith, Arkansas 72916
Little Rock, Arkansas 72223
Fountain Valley, California 92708
San Diego, California 92123
Washington, District of Columbia 20037
Chicago, Illinois 60611
Indianapolis, Indiana 46520
Kansas City, Kansas 66160
Louisville, Kentucky 40215
Rockville, Maryland 20850
Missoula, Montana 59808
Lebanon, New Hampshire 03756
East Windsor, New Jersey 08520
Bronx, New York 10467
East Syracuse, New York 13057
Forest Hills, New York 11375
New York, New York 10012
New York, New York 10029
Asheville, North Carolina 28801
Chapel Hill, North Carolina 27516
Winston-Salem, North Carolina 27157
Portland, Oregon 97239
Pittsburgh, Pennsylvania 15241
Charleston, South Carolina 29425
El Paso, Texas 79902
Murray, Utah 84107
Murray, Utah 84107
Richmond, Virginia 23219
Mill Creek, Washington 98012
Milwaukee, Wisconsin 53226
Alexandria Cook
414-266-6165
More Details
- NCT ID
- NCT03661866
- Status
- Recruiting
- Sponsor
- Target PharmaSolutions, Inc.
Detailed Description
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.